$2bn Biotech Hedge Fund | Senior Analyst

LifeSci Search

📍New York, NY
Posted May 24, 2026

Job Overview

Position

$2bn Biotech Hedge Fund | Senior Analyst

Company

LifeSci Search

Location

New York, NY

Work Type

On-site

Job ID

li-4399042910

Job Description

Our client is a biotech hedge fund with $2bn AUM that has consistently outperformed peer funds and the NBI. The team operates with a lean structure, led by 2 Founders from top tier life sciences funds and supported by 4 additional Investment Professionals. This is a true career track role, with an expectation and encouragement to stay long term and a clear historical precedent of promoting from within. The team is based in NYC with onsite work most of the week and some flexibility. The fund is long only with the ability to invest privately as needed, taking a venture style approach to the public markets with a highly concentrated portfolio.

Responsibilities

  • Conduct qualitative and quantitative fundamental analysis of companies, including assessment of competitive advantage, management team, and industry structure

  • Perform in-depth investment research: including both independent and due diligence such as speaking company management teams and industry experts, and analyzing publicly available data such SEC documents, company conference calls

  • Conduct detailed fundamental analyses of companies and industries, building financial forecast models, performing valuation analyses, and assessing the risks.

  • Analyze financial metrics of companies by evaluating historical performance and building models of financial statements, including proprietary forecasts

  • Performs valuation analyses on companies, including price targets as well as upside and downside valuation

  • Actively monitor existing holdings and investment opportunities within market

  • Support Sales and Marketing teams with external communications as assigned

  • Keep abreast of industry approaches and best practices and integrates findings into work as appropriate

  • Participate in ad hoc research projects as needed

  • Related duties and projects as assigned

Qualifications

  • 2+ years’ experience in Biotech Investment, Equity Research, Consulting, Investment Banking, etc..

  • Advanced scientific degree (MD, PhD, PharmD) preferred but not required

  • Excellent research, financial modeling, analytical, and valuation skills

  • Passion for financial analysis, company analysis, and industry research

  • Excellent verbal and written communications skills with the ability to communicate complex subject matter

  • Demonstrates strong analyst acumen

  • Ability to work well independently, prioritize, and manage time effectively in a dynamic and changing environment

  • Demonstrates good working relationships with all departments

Interview Prep

AI-powered insights to help you prepare

Key Skills

Required:
Preferred:

Practice Questions

💡Technical Questions (3)
  • 1.Given our fund's venture-style approach to public markets with a highly concentrated portfolio, how do you approach valuation for a pre-commercial biotech company with no revenue?
  • 2.Walk me through your process for evaluating the competitive advantage and industry structure of a novel therapeutic area before initiating a position.
  • 3.How do you incorporate management team assessments and expert network calls into your financial forecasts and risk assessments?
🎯Behavioral Questions (3)
  • 1.Tell me about a time you identified a critical risk in a biotech investment that others overlooked, and how you communicated this to your team.
  • 2.Describe a situation where you had to manage multiple competing priorities, such as monitoring existing holdings while researching a new time-sensitive opportunity.
  • 3.Give an example of a time you had to explain a complex scientific or financial concept to a non-technical audience, such as the Sales and Marketing team.
🧩Situational Questions (2)
  • 1.You are analyzing a small-cap biotech company for our concentrated long portfolio. The clinical data looks promising, but management has a poor track record of capital allocation and execution. How do you proceed?
  • 2.An existing holding in our portfolio drops 30% pre-market on the announcement of a missed Phase 2 primary endpoint that you did not anticipate. What are your immediate next steps?

Interested in this position? Apply directly on LinkedIn.

Apply on LinkedIn →